Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC

CEO Cameron Turtle walks us through the data, shares his opinion on its translatability to part B of the current study, and tells us what else is ahead for Spyre.

Episode metadata supplied by the publisher feed · Published Apr 13, 2026

Embed this episode

Attribution link and audio player

Ready to play

Spyre Therapeutics announced today that SPY001, an extended half-life α4β7, showed a 40% clinical remission rate at 12 weeks in moderate-to-severe UC

0:00 13:21

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 13 minutes long.

When was this BiotechTV - News episode published?

This episode was published on April 13, 2026.

Can I download this BiotechTV - News episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!